Palavras-chave
Infecções por HTLV-2
Imunoensaio Quimioluminescente de Micropartículas (CMIA)
Reação em Cadeia da Polimerase em Tempo Real
Doadores de Sangue
Como Citar
Resumo
O estudo tem como objetivo correlacionar às distribuições das razões sample-to-cutoff (S/CO) de resultados reagentes para anticorpos HTLV-1/2 com a detecção de DNA proviral em uma população de candidatos à doação de sangue. Realizou-se uma busca retrospectiva de dados de 632 amostras reagentes para HTLV-1/2 submetidas à testagem confirmatória entre janeiro de 2015 a dezembro de 2019. A triagem sorológica foi realizada pelo imunoensaio quimioluminescente de micropartículas Architect rHTLV-I/II, enquanto o teste confirmatório foi realizado pelo método de PCR em tempo real in-house. 496 de 632 amostras (78%) apresentaram DNA proviral indetectável e 136 (22%) apresentaram DNA proviral detectável. A infecção por HTLV não foi confirmada em nenhum indivíduo com valor de S/CO <4 e as taxas de detecção de DNA proviral escalonaram gradualmente à medida que as razões S/CO aumentaram. A sensibilidade e valor preditivo positivo encontrados para o Architect rHTLV-I/II foram 100% e 22%, respectivamente. Utilizando análise de curva ROC, o valor de razão S/CO ideal para predizer a presença de DNA proviral foi de 18,11. Razões S/CO elevadas foram mais associadas à detecção de DNA proviral. Em suma, o valor de S/CO <4 sugere a exclusão de infecção por HTLV e o risco de transmissão pelo sangue.
Referências
1. International Committee on Taxonomy of Viruses – ICTV. Taxonomy history: primate T-lymphotropic virus 1; 2019. [Accessed on 2022 Mar 23]. Available from: https://talk.ictvonline.org/taxonomy/p/taxonomy-history?taxnode_id=201904999
2. Lima VFS, Torres RM, Guerra FM, Carvalho TL, Magalhães PMR. Human T-cell lymphotropic viruses (HTLV-1 and HTLV-2): literature review. Braz J Health Rev. 2021;4(5):20900-23. https://doi.org/10.34119/bjhrv4n5-193
3. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 1980;77(12):7415-9. https://doi.org/10.1073/pnas.77.12.7415
4. Forlani G, Shallak M, Accolla RS, Romanelli MG. HTLV-1 infection and pathogenesis: new insights from cellular and animal models. Int J Mol Sci. 2021;22(15):8001. https://doi.org/10.3390/ijms22158001
5. Martinez MP, Al-Saleem J, Green PL. Comparative virology of HTLV-1 and HTLV-2. Retrovirology. 2019;16(1):21. https://doi.org/10.1186/s12977-019-0483-0
6. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. https://doi.org/10.3389/fmicb.2012.00388
7. Catalan-Soares B, Carneiro-Proietti ABF, Proietti FA; Interdisciplinary HTLV Research Group. Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saúde Pública. 2005;21(3):926-31. https://doi.org/10.1590/S0102-311X2005000300027
8. Maneschy CA, Barile KAS, Castro JAA, Palmeira MK, Castro RBH, Amaral CEM. Seroprevalence of the Human T Lymphotropic Virus (HTLV 1 and HTLV 2) in blood donor candidates in the state of Pará, Northern Brazil. Res Soc Dev. 2022;11(4):e1111427082. https://doi.org/10.33448/rsd-v11i4.27082
9. Mendes MFC, Lima JRO, Melo BO, Pinto CMFS, Maia HS, Ferro TAF et al. Molecular detection of human T cell lymphotropic virus type 1 in pregnant women from Maranhão state, Brazil. Braz J Microbiol. 2020;51(2):637-45. https://doi.org/10.1007/s42770-020-00233-0
10. Coordenação Geral de Vigilância das Infecções Sexualmente Transmissíveis: Grupo técnico de especialistas em HTLV. Prevalência da infecção por HTLV-1/2 no Brasil. Boletim Epidemiológico SVS/MS. 2020;51(48):25-33.
11. Maneschy CA, Barile KAS, Castro JAA, Palmeira MK, Castro RBH, Amaral CEM. Epidemiological and molecular profile of blood donors infected with HTLV-1/2 in the state of Pará, northern Brazil. Braz J Microbiol. 2021;52(4):2001-6. https://doi.org/10.1007/s42770-021-00609-w
12. Gross C, Thoma-Kress AK. Molecular mechanisms of HTLV-1 cell-to-cell transmission. Viruses. 2016;8(3):74. https://doi.org/10.3390/v8030074
13. Eusebio-Ponce E, Anguita E, Paulino-Ramirez R, Candel FJ. HTLV-1 infection: an emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. Rev Esp Quimioter. 2019;32(6):485-96.
14. Rosadas C, Brites C, Arakaki-Sanchez D, Casseb J, Ishak R. Brazilian Protocol for Sexually Transmitted Infections 2020: human T-cell lymphotropic virus (HTLV) infection. Rev Soc Bras Med Trop. 2021;54(Suppl 1):e2020605. https://doi.org/10.1590/0037-8682-605-2020
15. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019;133(17):1854-64. https://doi.org/10.1182/blood-2018-11-833996
16. Caterino-de-Araujo A, Gonçalves MG. Diagnóstico molecular de vírus T-linfotrópico humano (HTLV): histórico e estado da arte. BEPA, Bol Epidemiol Pauli. 2021;18(212):14-62.
17. Ministério da Saúde (BR). Portaria de consolidação n° 5, de 28 de setembro de 2017. Consolidação das normas sobre as ações e os serviços de saúde do Sistema Único de Saúde. Anexo IV. Diário Oficial da União. Brasília, DF, 2017. Available from: https://www.gov.br/saude/pt-br/composicao/sctie/farmacia-popular%20old/legislacao/prc-5-portaria-de-consolida-o-n-5-de-28-de-setembro-de-2017.pdf/@@download/file/PRC-5-Portaria-deConsolida----o-n---5--de-28-de-setembro-de-2017.pdf
18. Ji H, Chang L, Yan Y, Jiang X, Sun H, Guo F et al. A Strategy for screening and confirmation of HTLV-1/2 infections in Low-Endemic Areas. Front Microbiol. 2020;11:1151. https://doi.org/10.3389/fmicb.2020.01151
19. Andrade RG, Ribeiro MA, Namen-Lopes MSS, Silva SMN, Basques FV, Ribas JG et al. Evaluation of the use of real-time PCR for human T cell lymphotropic virus 1 and 2 as a confirmatory test in screening for blood donors. Rev Soc Bras Med Trop. 2010;43(2):111-15. https://doi.org/10.1590/s0037-86822010000200001
20. Campos KR, Santos FLN, Brito VS, Gonçalves NLS, Araujo THA, Galvão-Castro B et al. Line immunoassay for confirmation and discrimination of human T-cell lymphotropic virus infections in inconclusive western blot serum samples from Brazil. J Clin Microbiol. 2019;58(1):e01384-19. https://doi.org/10.1128/JCM.01384-19
21. Marqué L, Liehl P, De Boer J, Pottel H, Murphy EL, Bruhn R et al. A novel high performing multiplex immunoassay multi-HTLV for serological confirmation and typing of HTLV infections. PLoS Negl Trop Dis. 2021;15(11):e0009925. https://doi.org/10.1371/journal.pntd.0009925
22. Kiely P, Walker K, Parker S, Cheng A. Analysis of sample-to-cutoff ratios on chemiluminescent immunoassays used for blood donor screening highlights the need for serologic confirmatory testing. Transfusion. 2010;50(6):1344-51. https://doi.org/10.1111/j.1537-2995.2009.02572.x
23. Stramer SL, Notari EP, Zou S, Krysztof DE, Brodsky JP, Tegtmeier GE et al. Human T-lymphotropic virus antibody screening of blood donors: rates of false-positive results and evaluation of a potential donor reentry algorithm. Transfusion. 2011;51(4);692-701. https://doi.org/10.1111/j.1537-2995.2010.02903.x
24. Tosswill JHC, Taylor GP. Interpretation of low reactivity in the Abbott Architect rHTLV I/II assay. Transfus Med. 2018;28(4):326-30. https://doi.org/10.1111/tme.12482
25. Tamegão-Lopes BP, Rezende PR, Maradei-Pereira LMC, Lemos JAR. HTLV-1 and HTLV-2 proviral load: a simple method using quantitative real-time PCR. Rev Soc Bras Med Trop. 2006; 39(6):548-52. https://doi.org/10.1590/S0037-86822006000600007
26. Pham D, Nguyen D, Nguyen TA, Tran C, Tran L, Devare S et al. Seroprevalence of HTLV-1/2 among voluntary blood donors in Vietnam. AIDS Res Hum Retroviruses. 2019;35(4):376-81. https://doi.org/10.1089/aid.2018.0240
27. Zhao J, Zhao F, Han W, Xu X, Wang L, Li R et al. HTLV screening of blood donors using chemiluminescence immunoassay in three major provincial blood centers of China. BMC Infect Dis. 2020;20(1):581. https://doi.org/10.1186/s12879-020-05282-2
28. Murphy EL, Cassar O, Gessain A. Estimating the number of HTLV-2 infected persons in the world. Retrovirology. 2015;12(Suppl 1):O5. https://doi.org/10.1186/1742-4690-12-S1-O5
29. Murphy EL, Lee TH, Chafets D, Nass CC., Wang B, Loughlin K et al. Higher human T lymphotropic virus (HTLV) provirus load is associated with HTLV-I versus HTLV-II, with HTLV-II subtype A versus B, and with male sex and a history of blood transfusion. J Infect Dis. 2004;190(3):504-10. https://doi.org/10.1086/422398
30. Waters A, Oliveira AL, Coughlan S, de Venecia C, Schor D, Leite AC et al. Multiplex real-time PCR for the detection and quantitation of HTLV-1 and HTLV-2 proviral load: addressing the issue of indeterminate HTLV results. J Clin Virol. 2011;52(1):38-44. https://doi.org/10.1016/j.jcv.2011.05.022
31. Matsumoto C, Sagara Y, Sobata R, Inoue Y, Morita M, Uchida S et al. Analysis of HTLV-1 proviral load (PVL) and antibody detected with various kinds of tests in Japanese blood donors to understand the relationship between PVL and antibody level and to gain insights toward better antibody testing. J Med Virol. 2017;89(8):1469-76. https://doi.org/10.1002/jmv.24802
32. Yun SG, Kim, SW, Sohn JY, Cho Y. Evaluation of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II assay with Korean samples. J Clin Lab Anal. 2019;33(6):e22909. https://doi.org/10.1002/jcla.22909
33. Al-Hababi FH, Al-Deailej IM, Al-Sulatan HA, Al-Ghamdi YA, Al-Dossari KM. Human T lymphotropic virus antibodies seroprevalence among healthy blood donors and high risk groups at Riyadh regional laboratory in Riyadh, Saudi Arabia. Saudi Crit Care J. 2020;4(2):73-8. https://doi.org/10.4103/sccj.sccj_13_20
34. Laperche S, Sauleda S, Piron M, Mühlbacher A, Schennach H, Schottstedt V et al. Evaluation of sensitivity and specificity performance of elecsys HTLV-I/II assay in a multicenter study in Europe and Japan. J Clin Microbiol. 2017;55(7):2180-7. https://doi.org/10.1128/JCM.00169-17
35. Brito VS, Santos FLN, Gonçalves NLS, Araujo THA, Nascimento DSV, Pereira FM et al. Performance of commercially available serological screening tests for human T-cell lymphotropic virus infection in Brazil. J Clin Microbiol. 2018;56(12):e00961-18. https://doi.org/10.1128/JCM.00961-18
36. World Health Organization – WHO. Screening donated blood for transfusion-transmissible infections: recommendations. Genebra: World Health Organization; 2010.
Chang L, Ou S, Shan Z, Zhu F, Ji H, Rong X et al. Seroprevalence of human T-lymphotropic virus infection among blood donors in China: a first nationwide survey. Retrovirology. 2021;18(1):2. https://doi.org/10.1186/s12977-020-00546-w
38. Kiely P, Hoad VC, Wood EM. False positive viral marker results in blood donors and their unintended consequences. Vox Sang. 2018;113(6):530-9. https://doi.org/10.1111/vox.12675
39. Vo MT, Bruhn R, Kaidarova Z, Custer BS, Murphy EL, Bloch EM. A retrospective analysis of falsepositive infectious screening results in blood donors. Transfusion. 2016;56(2):457-65. https://doi.org/10.1111/trf.13381
40. Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health. 2017;5:307. https://doi.org/10.3389/fpubh.2017.00307
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Lucas José do Nascimento Cruz, Carolina de Alcântara Maneschy, Katarine Antonia do Santos Barile, Maurício Koury Palmeira, Carlos Eduardo de Melo Amaral